The economic impact of the usability advantage of IN glucagon over IM glucagon was explored in cost offset and budget impact analyses for the US setting, for T1D and T2D patients treated with basal–bolus insulin regimens. This evidence concerns the gene GCG and type 1 diabetes mellitus.